{
  "id": 19494464,
  "title": "Cantor raises NewAmsterdam Pharma stock price target to $61",
  "url": "https://urgent.news/2026/11/11/cantor-raises-newamsterdam-pharma-stock-price-target-to-61",
  "topic": "world",
  "section": "World",
  "published": "2026-11-11T12:30:54.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/cantor-raises-newamsterdam-pharma-stock-price-target-to-61-93CH-5018673"
  },
  "original_language": "en",
  "account": "Investing.com reports that Cantor Fitzgerald boosted its price target for NewAmsterdam Pharma Co NV (NASDAQ:NAMS) to $61, up from $52, while keeping an Overweight rating. The stock, which is trading at $19.18 and near its 52-week low of $17.90, has upside potential of over 200% to the new target. Shares have dropped 8.4% in the past week and 52% over six months. Cantor also increased its probability-of-success for obicetrapib from 65% to 75% and adjusted its revenue and expense estimates accordingly. They removed 2027 U.S. obicetrapib revenue from their estimates based on feedback from NewAmsterdam Pharma. The $61 price target is based on a discounted cash flow model. Despite NAMS appearing overvalued relative to its Fair Value, analyst targets suggest significant upside potential.",
  "summary": null,
  "key_points": [
    "Cantor Fitzgerald raises NAMS stock target to $61 from $52.",
    "Analyst upgrades rating to Overweight with 75% success probability.",
    "$61 target based on discounted cash flow model despite overvaluation."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}